Date: 2017-04-13

Type of information: Licensing agreement

Compound: BMS-986168

Company: BMS (USA - NY) Biogen (USA - CA)

Therapeutic area: Rare diseases - Neurodegenerative diseases - Neurological diseases

Type agreement: licensing

Action mechanism: monoclonal antibody. BMS-986168 is a monoclonal antibody designed to bind to and decrease levels of extracellular Tau (eTau) protein. It is currently being investigated as a treatment option for patients with PSP, with the potential for future development in other neurodegenerative diseases such as Alzheimer’s disease.

Disease: progressive supranuclear palsy

Details: • On April 13, 2017, BMS announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for progressive supranuclear palsy (PSP), to Biogen.    

Financial terms: Under the agreement to license BMS-986168, Biogen will pay to BMS an upfront payment of $300 million with potential milestone payments of up to $410 million. Biogen also will assume all remaining obligations to the former stockholders of iPierian, Inc. related to BMS’ acquisition of the company in 2014.

Latest news:

Is general: Yes